Clinical Trials Logo

Filter by:
NCT ID: NCT01239732 Completed - Ovarian Cancer Clinical Trials

A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer

Start date: December 2010
Phase: Phase 3
Study type: Interventional

This open-label, non-comparative, multi-center study will assess the safety profile and efficacy of Avastin (bevacizumab) when added to carboplatin and paclitaxel therapy in patients with epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma. Patients will receive 15 mg/kg Avastin intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each, carboplatin (AUC 5-6 mg/ml/min) on Day 1 every 3 weeks for a maximum of 8 cycles and paclitaxel 175 mg/m2 on Day 1 every 3 weeks or 80 mg/m2 every week for a maximum of 8 cycles. The anticipated time on study drug will be 108 weeks or until disease progression or unacceptable toxicity.

NCT ID: NCT01238640 Completed - Tobacco Dependence Clinical Trials

Bioequivalence Between Two New Oral Nicotine Replacement Therapy Products and Nicorette® Microtab

Start date: August 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the bioequivalence between two new oral nicotine replacement therapy products and Nicorette® microtab.

NCT ID: NCT01238627 Completed - Tobacco Dependence Clinical Trials

Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg

Start date: September 2007
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the bioequivalence between two oral nicotine sublingual tablets, 2 mg and 4 mg.

NCT ID: NCT01238224 Terminated - Type 2 Diabetes Clinical Trials

Effects of PDE-5 Inhibition on Postprandial Hyperglycemia in Type 2 Diabetes

Start date: November 2009
Phase: Phase 1
Study type: Interventional

An increase of blood flow and capillary permeability decrease the impact of an endothelial barrier for glucose and insulin allowing them to reach their target cells in peripheral insulin sensitive organ in the human body. It is well known that insulin-resistant type 2 diabetes patients have an impaired blood flow in skeletal muscle and it is therefore important to elucidate means to reverse this metabolic defect. The investigators have in a recently published study in type 2 diabetes patients used a drug against erectile dysfunction, the PDE-5 inhibitor tadalafil, with known effects on several vascular territories, to increase muscle blood flow in type 2 diabetes patients who were studied after fasting overnight. The aim of this study is to test the hypothesis that tadalafil, compared to placebo, increases muscle glucose uptake and lowers blood glucose following a mixed meal served to type 2 diabetes patients.

NCT ID: NCT01237743 Completed - Aortic Stenosis Clinical Trials

Microembolic Signals and Serum Markers of Neuronal Damage During Transcatheter Aortic Valve Implantation.

Start date: July 2009
Phase: N/A
Study type: Observational

Transcatheter Aortic Valve Implantation (TAVI) using femoral access is an option for definitive treatment of aortic stenosis when open-heart surgery is considered inappropriate. By avoiding the effects of cardiopulmonary bypass on cerebral hemodynamics and microembolic load, TAVI is assumed to be beneficial regarding risk for neurological complications. We anticipated that the extensive endovascular retrograde manipulation in ascending aorta and aortic root would generate a detectable cerebral microembolic load, and thus an increase in serological markers of neuronal injury postoperatively. Our hypothesis is that there is a positive correlation between the total amount of cerebral microembolic events during the TAVI procedure and the Area under curve (AUC24hrs) for the release pattern of two markers of neuronal injury. We also wish to describe the extent and distribution of microembolisms during the TAVI procedure using Transcranial Doppler (TCD).

NCT ID: NCT01235598 Completed - Clinical trials for Rheumatoid Arthritis

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)

MARVELOUS
Start date: December 2010
Phase: Phase 3
Study type: Interventional

Phase IIIb study to determine early response to Certolizumab Pegol (CZP) with Magnetic Resonance Imaging (MRI) score Outcome Measures in Rheumatoid Arthritis (RA) Clinical Trials (OMERACT) RA MRI Scoring System (RAMRIS) in subjects with RA.

NCT ID: NCT01235520 Completed - Schizophrenia Clinical Trials

A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

Start date: January 2011
Phase: Phase 3
Study type: Interventional

This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia. Patients, on stable treatment with antipsychotics, will be randomized to receive daily oral doses of RO4917838 or matching placebo for 52 weeks, followed by an optional treatment extension for up to 3 years.

NCT ID: NCT01235364 Completed - Pain Clinical Trials

Assessment of Pain With Insertion of the Foley Catheter for Induction of Labour

Start date: August 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to assess pain in women randomised to digital or speculum placement of a Foley catheter. Pain during cervical ripening with the Foley catheter is also to be evaluated as well as maternal satisfaction with induction of labour.

NCT ID: NCT01234961 Completed - Clinical trials for Burnout, Professional

Outcome Study of the ReDO Intervention for Women With Stress-related Disorders

Start date: September 2007
Phase: N/A
Study type: Interventional

This project evaluates the outcomes of a work rehabilitation program, Redesigning Daily Occupations (ReDO), for women with stress-related disorders. The ReDO intervention focuses on how people compose their everyday lives. The basic idea is that re-structuring of an individual's lifestyle and pattern of daily occupations will lead to a healthier balance between the occupations of everyday life, and that this balance will promote wellness and increased work capacity. The program is group based and comprises 16 weeks. The aim is to evaluate ReDO for women with stress-related disorders. The project, which covers the time period from entering the program to a 12-month follow-up, is a quasi-experimental study. 42 women who entered the program and fitted the selection criteria were included. A matched comparison group was selected among those clients at the Social Insurance Office who get "care-as-usual" (CAU). Both groups are followed prospectively and are compared regarding return to work, sick leave, and different aspects of health and well-being. The hypothesis is that the ReDO group will improve more than the CAU group in all these respects.

NCT ID: NCT01234896 Completed - Tobacco Dependence Clinical Trials

Single-dose Nicotine Pharmacokinetics With Four Oral Nicotine Replacement Products

Start date: October 2010
Phase: N/A
Study type: Interventional

Single-dose nicotine pharmacokinetics with four oral nicotine replacement products. A study in healthy smokers.